You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物(1801.HK)漲近5% 與UNION therapeutics合作 引進下一代PDE4抑制劑
格隆匯 09-28 13:18
格隆匯9月28日丨信達生物(1801.HK)漲近5%,暫錄四連漲,報76.9港元,總市值1122億港元。信達生物今日與UNION therapeutics共同宣佈,雙方就後者用於治療炎症性皮膚病的主要候選藥物orismilast,達成在中國(包括中國大陸、香港、澳門和台灣地區)的獨家授權協議。這是一款處於臨牀2期的潛在“best-in-class”PDE4抑制劑。根據協議條款,信達生物將獲得orismilast在中國研究、開發和商業化的獨家權益。UNION公司將收到2000萬美元的首付款,並有權獲得累計不超過2.47億美元的里程碑付款,以及orismilast在中國年度銷售淨額的特許權使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account